机构:[1]Joint Division of Clinical Epidemiology, Affiliated Hospital of Nantong University, School of Public Health of Nantong University, Nantong, China[2]Macquarie University Centre for the Health Economy, Macquarie Business School & Australian Institute of Health Innovation, Macquarie University, Macquarie Park, New South Wales, Australia[3]Department of Internal Medicine, Medical School of Nantong University, Nantong, Jiangsu, China[4]Department of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China临床科室耳鼻咽喉-头颈外科首都医科大学附属北京同仁医院首都医科大学附属同仁医院[5]Beijing Institute of Otolaryngology, Beijing, China研究所耳鼻咽喉科研究所首都医科大学附属北京同仁医院首都医科大学附属同仁医院[6]Key Laboratory of Otolaryngology Head and Neck Surgery, Ministry of Education, Beijing, China首都医科大学附属同仁医院[7]Department of Epidemiology and Biostatistics, School of Public Health of Nantong University, Nantong, Jiangsu, China[8]Department of Paediatrics, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China[9]Department of Medical Genetics, Nantong Maternal and Child Health Care Hospital, Nantong, Jiangsu, China[10]Department of Otolaryngology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
Background While global newborn hearing screening programmes (NHSP) are far from the optimal level, the combined hearing and genetic screening has emerged as an innovative approach of early healthcare interventions. There is a clear need for economic evaluation to establish whether newborn deafness gene screening (NDGS), currently mandated by many cities in China, is a good investment.Methods A decision-tree model was constructed to simulate a hypothetical 10-million Chinese newborn cohort over a lifetime with three strategies: (1) no screening, (2) NHSP (standard screening) and (3) NHSP+NDGS (combined screening). The presence of permanent congenital hearing loss (PCHL) and genetic mutation were assigned at birth and held constant for all strategies. Input parameters were obtained from the Cohort of Deafness-gene Screening study and literature review. The government contract price for genetic screening was US$77/child. Outcomes of interest included the number of early diagnosed PCHL, prelingual deafness, total deafness, special education referral, incremental cost-effectiveness ratio (ICER) and benefit-cost ratio (BCR).Results Both standard and combined screening strategies were more effective and more costly than 'no screening'. Compared with standard screening, combined screening led to 9112 (28.0%) more PCHL cases early detected, avoiding 4071 (66.9%) prelingual deafness cases and 3977 (15.6%) special education referrals. The ICER and BCR for combined screening were US$ 4995/disability-adjusted life-year (95% uncertainty interval, 2963 to 9265) and 1.78 (1.19 to 2.39), from healthcare sector perspective. Combined screening would dominate standard screening from societal perspective. Moreover, it remained cost-effective even in pessimistic scenarios.Conclusions Our findings have particular implication for the 'scale-up' of genetic screening at the national level in China. The model may serve as a feasible example for hearing screening strategies in other countries, as well as genetic screening for other diseases.
基金:
National Natural Science Foundation of China [82071064, 81870730]; National Research and Development Program of China [2018YFC1002200]; Jiangsu Provincial Key Research and Development Programme [BE2015655, BE2022764]; Science and Technology Project of Nantong City [MS22022086]
语种:
外文
被引次数:
WOS:
第一作者:
第一作者机构:[1]Joint Division of Clinical Epidemiology, Affiliated Hospital of Nantong University, School of Public Health of Nantong University, Nantong, China
共同第一作者:
通讯作者:
通讯机构:[4]Department of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China[5]Beijing Institute of Otolaryngology, Beijing, China[6]Key Laboratory of Otolaryngology Head and Neck Surgery, Ministry of Education, Beijing, China
推荐引用方式(GB/T 7714):
Shu Jun-Tao,Gu Yuan-Yuan,Zhai Pei-Yao,et al.Economic evaluation of newborn deafness gene screening as a public health intervention in China: a modelling study[J].BMJ PUBLIC HEALTH.2024,2(1):doi:10.1136/bmjph-2023-000838.
APA:
Shu, Jun-Tao,Gu, Yuan-Yuan,Zhai, Pei-Yao,Wen, Cheng,Qian, Min...&Qin, Gang.(2024).Economic evaluation of newborn deafness gene screening as a public health intervention in China: a modelling study.BMJ PUBLIC HEALTH,2,(1)
MLA:
Shu, Jun-Tao,et al."Economic evaluation of newborn deafness gene screening as a public health intervention in China: a modelling study".BMJ PUBLIC HEALTH 2..1(2024)